Just spent some time poking around the theraquest website, and can't say that I would be concerned about injectable ketoprofen, at least for a while. They claim it is in development, but there is nothing on the clinicaltrials.org website, nor is the co. making any statement on their site about clinical trial(s).
Theraquest appears to have a couple of interesting ventures, including a sustained release formulation for tramadol (which is about as slow acting an opiate as they come already) and an orphan status for topical capcaisin. I don't think that tramadol needs any more slowing in its mechanism of onset. Their other drug candidates sound like formulations of tramadol and other analgesics that keep the opiate "buzz" low enough to lower the addiction potential.
Theraquests data is limited to one human study for injectable ketaprofen, and several animal model studies for their opiate candidates. The Ketaprofen study looks OK, but it compared 50 and 100 mg ketaprofen with 4 mg. morphine and placebo, rather than Toradol (which they cite in their first sentence of the presentation as the only available NSAID for post-operative pain). there has apparently been no update, and no head to head comparison with Toradol. If this is going to happen, they have alot of work to do.
It appears that this co. is the brainchild of a pharmacist who is trying to put together some opiate formulations and market them to other co.'s and was smart enough to recognize the orphan status as a way to carve out another niche for his co.
FWIW
aj
Market Data 
Markets 
AI
